These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 31948539)

  • 61. Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.
    Carbone DP; Gandara DR; Antonia SJ; Zielinski C; Paz-Ares L
    J Thorac Oncol; 2015 Jul; 10(7):974-84. PubMed ID: 26134219
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Active specific immunotherapy with an autologous tumor cell vaccine in patients with resected non-small cell lung cancer.
    Schulof RS; Mai D; Nelson MA; Paxton HM; Cox JW; Turner ML; Mills M; Hix WR; Nochomovitz LE; Peters LC
    Mol Biother; 1988; 1(1):30-6. PubMed ID: 2855788
    [TBL] [Abstract][Full Text] [Related]  

  • 63. [Non-Small Cell Lung Cancer - from Immunobiology to Immunotherapy].
    Bílek O; Bohovicová L; Demlová R; Poprach A; Lakomý R; Zdražilová-Dubská L
    Klin Onkol; 2016; 29 Suppl 4(Suppl 4):78-87. PubMed ID: 27846725
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity.
    Rossi S; Castello A; Toschi L; Lopci E
    Immunotherapy; 2018 Jul; 10(9):797-805. PubMed ID: 30008262
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Immunotherapy for thoracic oncology gone viral.
    Patel MR
    Immunotherapy; 2018 Apr; 10(5):383-390. PubMed ID: 29473469
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities.
    Suresh K; Naidoo J; Lin CT; Danoff S
    Chest; 2018 Dec; 154(6):1416-1423. PubMed ID: 30189190
    [TBL] [Abstract][Full Text] [Related]  

  • 67. How to Increase the Efficacy of Immunotherapy in NSCLC and HNSCC: Role of Radiation Therapy, Chemotherapy, and Other Strategies.
    Nardone V; Pastina P; Giannicola R; Agostino R; Croci S; Tini P; Pirtoli L; Giordano A; Tagliaferri P; Correale P
    Front Immunol; 2018; 9():2941. PubMed ID: 30619301
    [No Abstract]   [Full Text] [Related]  

  • 68. Immunotherapy for lung cancer: for whom the bell tolls?
    Madureira P; de Mello RA; de Vasconcelos A; Zhang Y
    Tumour Biol; 2015 Mar; 36(3):1411-22. PubMed ID: 25736929
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Lung cancer adjuvant therapy.
    Horn L; Sandler A
    Cancer J; 2007; 13(3):210-6. PubMed ID: 17620772
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
    Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
    J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A review of eligibility for patients with central nervous system (CNS) metastases from non-small cell lung cancer (NSCLC) in immunotherapy clinical trials.
    Shaikh SS; Kumthekar PU; Mohindra NA
    J Neurooncol; 2019 Aug; 144(1):235-237. PubMed ID: 31240523
    [No Abstract]   [Full Text] [Related]  

  • 72. Emerging biomarkers for immune checkpoint inhibition in lung cancer.
    Cyriac G; Gandhi L
    Semin Cancer Biol; 2018 Oct; 52(Pt 2):269-277. PubMed ID: 29782924
    [TBL] [Abstract][Full Text] [Related]  

  • 73. [Vaccines for the treatment of non-small cell lung cancer].
    Leduc C; Quoix E
    Rev Mal Respir; 2019 Mar; 36(3):415-425. PubMed ID: 30902445
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Immunotherapy and multidisciplinary approach to treatment in lung cancer].
    Karadurmuş N; Kaya A; Göksel T; Yılmaz Ü; Tülek N
    Tuberk Toraks; 2020 Mar; 68(1):66-75. PubMed ID: 32718141
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer.
    Papachristofilou A; Hipp MM; Klinkhardt U; Früh M; Sebastian M; Weiss C; Pless M; Cathomas R; Hilbe W; Pall G; Wehler T; Alt J; Bischoff H; Geißler M; Griesinger F; Kallen KJ; Fotin-Mleczek M; Schröder A; Scheel B; Muth A; Seibel T; Stosnach C; Doener F; Hong HS; Koch SD; Gnad-Vogt U; Zippelius A
    J Immunother Cancer; 2019 Feb; 7(1):38. PubMed ID: 30736848
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Neoadjuvant treatment of non small cell lung cancer -- pro].
    Eberhardt W
    Dtsch Med Wochenschr; 2005 Sep; 130(38):2158. PubMed ID: 16172959
    [No Abstract]   [Full Text] [Related]  

  • 77. Clinical Approaches to Immunotherapy in Non-Small Cell Lung Cancer: Current and Future Perspectives.
    Rice SJ; Miller B; Wagman M; Jamorabo DS; Liu X; Belani CP
    Curr Mol Pharmacol; 2016; 9(3):183-195. PubMed ID: 26177648
    [TBL] [Abstract][Full Text] [Related]  

  • 78. The interaction of immune checkpoint inhibitor plus chemotherapy in non-small-cell lung cancer: subadditivity, additivity or synergism?
    Rassy E; Bakouny Z; Assi T; Karak FE; Pavlidis N
    Immunotherapy; 2019 Jul; 11(10):913-920. PubMed ID: 31188048
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Neoadjuvant immunotherapy in gastrointestinal cancers - The new standard of care?
    Petricevic B; Kabiljo J; Zirnbauer R; Walczak H; Laengle J; Bergmann M
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):834-850. PubMed ID: 35671877
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Progress in Immunotherapy for Squamous Non-small Cell Lung Cancer].
    Wang S; Li J
    Zhongguo Fei Ai Za Zhi; 2016 Oct; 19(10):682-686. PubMed ID: 27760599
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.